IDXX
IDEXX LABORATORIES INC /DEEvidence as of 2026-09-03Overview · IDEXX LABORATORIES INC /DE
IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and ra…
Management team
- Mr. Jeffery D. Chadbourne · Senior Vice President of Commercial Finance & Sales OperationsFind on LinkedIn
- Ms. Sharon E. Underberg · Executive VP, General Counsel, & Corporate SecretaryFind on LinkedIn
- Mr. Ken Grady · Senior VP & Chief Information OfficerFind on LinkedIn
- Dr. Martin Smith Ph.D. · Executive VP & CTOFind on LinkedIn
Start your 7-day free trial to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
Moneyta sentiment
Where the published evidence leans after the desk debated it — not a rating or a recommendation.
+0.2 on a −2 to +2 scale.
What builds the score
Solid bars are analyst rubric scores; faded bars are computed directly from data. Claims dropped in debate count for nothing; weakened claims count at half weight.
Editor's note
Written after the debate settled — the rest of the page is the evidence behind it.
The desk’s evidence balance is Mixed (+0.2 of a possible +2; confidence high). Quarter-by-quarter results show revenue of USD 1,109,457,000 for the quarter 2025-04-01 to 2025-06-30 (fiscal Q1 2025 — quarter ended 2025-04-28), USD 1,105,239,000 for 2025-07-01 to 2025-09-30 (fiscal Q3 2025 — quarter ended 2025-10-29), USD 1,140,820,000 for 2026-01-01 to 2026-03-31 (fiscal Q1 2026 — quarter ended 2026-04-30), and USD 1,216,585,000 for 2026-04-01 to 2026-06-30 (fiscal Q2 2026 — quarter ended 2026-07-31). Gross profit, operating income, and net income/EPS moved in step: gross profit rose from USD 694,732,000 to USD 779,087,000 across those quarters, operating income from USD 373,046,000 to USD 425,566,000, and net income from USD 293,989,000 (EPS 3.63) to USD 338,412,000 (EPS 4.27).
Capital structure and cash snapshots are intact in the packet: diluted share count declined from 80,994,000 to 79,312,000 (weighted-average diluted), point-in-time shares outstanding were 79,882,997 as of 2026-04-30 and 78,781,116 as of 2026-07-31, cash rose from USD 180,070,000 as of 2025-12-31 to USD 196,933,000 as of 2026-06-30, and long-term debt noncurrent moved from USD 374,842,000 to USD 299,865,000 over the same comparison points. Market signals are mixed: six-month momentum is negative at -16.9% (10th percentile of 547), twelve-month momentum is +9.8% (44th percentile), price sits below the 50- and 200-day SMAs ( -3.6% and -11.4%), trailing P/E is 36.49, P/FCF is 56.63, EV/EBITDA is 25.95, and trailing twelve-month FCF is USD 754,913,000.
How this note was made
every stage ran before the note was writtenAnalyst desk
Mercer, Oakes, Nash, Ellis, Yates, Talbot and Archer. The desk: named AI agents, not people. Each reads one slice of the evidence and nothing else — no outside knowledge, no browsing — so every finding traces to a source you can open.
Reads the XBRL figures companies file with the SEC — revenue, margins, income, debt and share count, quarter by quarter — and reports which way the trend is running.
Revenue was USD 1,109,457,000 for the quarter 2025-04-01 to 2025-06-30, USD 1,105,239,000 for 2025-07-01 to 2025-09-30, USD 1,140,820,000 for 2026-01-01 to 2026-03-31, and USD 1,216,585,000 for 2026-04-01 to 2026-06-30 (compare these quarterly figures directly).
XBRL companyfacts · 0000874716-25-000121Gross profit was USD 694,732,000 for the quarter 2025-04-01 to 2025-06-30, USD 683,354,000 for 2025-07-01 to 2025-09-30, USD 722,739,000 for 2026-01-01 to 2026-03-31, and USD 779,087,000 for 2026-04-01 to 2026-06-30.
XBRL companyfacts · 0000874716-25-000121Reads the filings themselves, above all the year-over-year diff of Item 1A risk factors: which risks a company added, dropped or quietly reworded since its last annual report.
Which filings the desk reads
The desk reads the annual 10-K in full — its risk factors, and how they changed since last year. Quarterly 10-Qs and event filings (8-Ks, insider Form 4s) are listed for context but not read line by line: the 10-K is where the material risk disclosures live. A brand-new company, or one we have only just begun tracking, may have no annual report on file yet — its risk analysis fills in once that lands.
A Form 4 for the company was filed on 2026-08-24 with the 4 filed 24 August 2026.
4 filed 2026-08-24The provided filing record shows parse_status marked as "skipped", indicating no parsed transaction details are available from this evidence item.
4 filed 2026-08-24Reads the signal panel above — momentum, volatility, drawdown, relative strength and beta — and ranks each against the whole research universe rather than judging it in isolation.
Six-month momentum was -16.9% as of 2026-09-02 and ranks in the 10th percentile of the 547-stock research universe, indicating this 6-month return is low relative to peers.
Moneyta signal set · 2026-09-02weakened in debateRelative strength versus SPY over six months was -28.9% as of 2026-09-02 and the cross-sectional rank is the 10th percentile of 547, showing the security underperformed the benchmark over that horizon compared with most peers.
Moneyta signal set · 2026-09-02Reads which funds hold the name and at what weight, plus insider Form 4 filings, to show the exposure you may already carry through index funds.
As of 2026-09-02T13:45:47.228469+00:00, the ETF IVV held 0.06% of its fund weight in this issuer.
ETF constituents · market dataA Form 4 insider filing (the 4 filed 24 August 2026) was filed on 2026-08-24 (parse_status: skipped; primary_doc_url: null).
Form 4 × 1 (90d window not enforced here)Reads recent headlines that are genuinely about this company, ignoring rating chatter and market-wide stories. Findings argue in the debate but never move the sentiment score.
A filing-based report said Two Sigma Securities LLC increased its IDEXX stake by 166.0% during the second quarter, leaving it with 2,636 shares after the change.
News · thelincolnianonline.com · 2026-09-01IDEXX announced that its CEO and CFO will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, a company event noted in multiple press-distribution outlets.
News · finance.yahoo.com · 2026-08-31Reads parsed Forms 3/4/5 — who bought or sold, at what size, and whether a 10b5-1 plan was involved. Flags clustered open-market officer buying; treats plan sales as routine and never counts a fund or 10%-holder as an officer.
Emerson Andrew (EVP, CFO and Treasurer) reported an action coded "M" on 2026-08-20 for 265 shares valued at "$47k" (amended: false); the filing shows no trading plan indicated.
Form 4 · Emerson Andrew (EVP, CFO and Treasurer) · $47k code M · 2026-08-20Emerson Andrew (EVP, CFO and Treasurer) reported an action coded "F" on 2026-08-20 for 86 shares valued at "$0" (amended: false); the filing shows no trading plan indicated.
Form 4 · Emerson Andrew (EVP, CFO and Treasurer) · $47k code M · 2026-08-20Reads the implied-expectations math built from the company's own filings (the growth rate today's price would justify, and the multiples beside it) and argues whether the market's bar looks high or low for this business. Never turns the math into a target.
The model reports an implied free cash flow (FCF) growth rate of 36.55% that today's price would justify under the stated discount and terminal assumptions.
Valuation inputs · SEC XBRL + stored EOD closePrice-to-free-cash-flow (P/FCF) on trailing twelve months FCF is 56.63.
Valuation inputs · SEC XBRL + stored EOD closeDebate and risk review
A bull and a bear contest the claims and the chair rules on each; the risk review stress-tests what survived.
A bull and a bear argue the analysts' claims across two rounds, then a chair rules on each one. Only what survives feeds the score — the argument is shown, not hidden, so you can judge the reasoning yourself.
The company’s reported operating and profitability metrics show sequential improvement across recent quarters: revenue (fundamentals-0), gross profit (fundamentals-1), operating income (fundamentals-2), and net income / EPS (fundamentals-3) all trend higher into 2026-Q2. Share count has declined (fundamentals-4), which amplifies reported EPS gains, and the balance-sheet snapshot shows higher cash and lower long-term noncurrent debt versus the prior year-end (fundamentals-5), supporting liquidity and capital structure improvement. Market underperformance over six months and price below moving averages (market-0, market-1, market-4) highlight short-term momentum weakness, but those are market-technical observations rather than company fundamental deterioration; coverage noted raised full-year guidance after fiscal Q2 2026 (news-2) and several analysts maintain buy/hold ratings, indicating ongoing institutional interest. Valuation ratios are elevated (valuation-0, valuation-1, valuation-2, valuation-3), however trailing free cash flow and operating cash flow levels (valuation-4) provide tangible cash-generation evidence that underpins the higher multiples.
Chair's verdict, claim by claim
Fragility · computed, not argued
balanced0.36
31 surviving claims rest on 14 distinct sources; the heaviest analyst carries 26% of them, and 97% of what the desk raised survived the debate.
The reading rests on a moderate number of distinct sources but a relatively concentrated analyst contribution and an unusually high survival rate from internal debate. That combination makes the package informative but brittle: a few sources or the main analyst carry outsized influence, and the high survival rate suggests limited internal skepticism removed potentially weak claims.
Peer context · computed, not argued
12-1 momentum ranks 4th of 5 in Diagnostics & Research (as of 2026-09-02).
6-month relative strength ranks 5th of 5 in Diagnostics & Research (as of 2026-09-02).
90-day volatility ranks 4th of 5 in Diagnostics & Research (as of 2026-09-02).
dividend yield ranks 4th of 5 in Diagnostics & Research (as of 2026-09-02).
Disconfirming evidence · base rates · falsifiers
Context
Outside consensus, and where this name already sits in your own portfolio.
Third-party consensus shown for context. It never enters Moneyta sentiment — when the two diverge, the debate above is where the why lives.
What this was built from
Every figure on this page traces to one of these. The desk reads only what is listed here — no outside knowledge, no browsing — and each card shows who read it and what it contributed to the score.
11 filings· 1 cited
SEC XBRL filings
Quarterly figures as filed with the SEC, read straight from EDGAR's structured data — not retyped or estimated.
Read by Mercer+1.8 to the score
1 document
SEC filing documents
The filings themselves, including the year-over-year comparison of Item 1A risk factors.
Read by Oakes+0.0 to the score
1 signal set
Moneyta signal set
Computed from our own end-of-day price history and ranked against the whole research universe. No AI involved.
Read by Nash−0.6 to the score
2 holdings records
Fund holdings
Which funds hold this name and at what weight, plus insider Form 4 filings.
Read by Ellis+0.0 to the score
8 headlines· 2 cited
News coverage
Recent headlines about this company, rating chatter excluded and nothing published after the report date.
Read by Yatesnothing survived
1 filing
Insider filings
Parsed Forms 3/4/5 from EDGAR: named insiders, share counts, prices, and 10b5-1 plan state — stated and inferred flags kept apart.
Read by Talbot+0.0 to the score
1 computation
Valuation inputs
TTM cash-flow figures from the company's own XBRL filings, priced with the stored closing price. Implied growth and multiples only; no fair-value dollar figure reaches the desk, by design.
Read by Archercontext only
1 record· 0 cited
Company profile
Sector, industry and company details.
1 record· 0 cited
Analyst consensus
Third-party consensus, shown for context only — it never enters Moneyta sentiment.
Read means we pulled and handed it to an analyst; cited means a claim on this page points at it. Reading twelve quarters to state one trend is normal — the gap is shown rather than hidden.
Written by AI, checked against sources
The analysts, the bull–bear debate and the editor's note are AI agents reading only the evidence listed on this page. They can misread a filing or a headline, which is why every claim cites a source you can open and check yourself. The sentiment score is arithmetic over the claims that survived the debate, not a language model's opinion.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations. Past patterns do not indicate future results.
Get this for the tickers you actually hold
Plus the one thing no sample can show: how each name correlates with your portfolio, and what hides inside your funds.
The full terminal on IDXX Gold
Who holds it, who's buying, what the Street thinks: live behind the lock, updated as filings land.
Institutional holders
Net institutional flow, Q/Q
Largest holder position
Insider buys, 90 days
Clustered insider value
Street target range
The real figures are for members. Educational analysis, not advice.
Educational analysis of published data. Moneyta does not give investment advice or make recommendations.